Fig. 4From: Impact of patient-reported outcomes on symptom monitoring during treatment with checkpoint inhibitors: health-related quality of life among melanoma patients in a randomized controlled trialFACT-M data for patients in the PROMelanoma study at baseline, week 24 and week 48, comparing the HRQoL between patients with no severe irAEs and patients with severe irAEsBack to article page